Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

More women vs. men veterans with COPD received spirometry and tobacco cessation interventions, but more men received correct ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Digital inhalers can detect significant changes in physiologic and inhaler use metrics in the 14 days before COPD exacerbations.

Avalyn Pharma has drawn in another fundraising round, this time a $100 million oversubscribed series D to continue developing ...

Patients with COPD and type 2 diabetes had a reduced risk for COPD hospitalization, noninvasive positive-pressure ventilation and all-cause mortality if they used an SGLT-2 inhibitor, according to ...

Tozorakimab, an anti-IL-33 antibody, improves lung function and may reduce exacerbations in high-risk COPD patients, early ...

In a statement on the approval, GSK said that a lower threshold means that nearly 70% of COPD patients in the US who are inadequately controlled on inhaled triple therapy could be eligible for Nucala.